Covid-19: Pfizer-BioNTech Vaccine Is “Likely” Responsible For Deaths of Some Elderly Patients, Norwegian Review Finds
▫️The Pfizer-BioNTech Covid-19 Vaccine Is “Likely” To Have Been Responsible For At Least 10 Deaths of Frail Elderly People In Nursing Homes In Norway, An Expert Review Commissioned by The Norwegian Medicines Agency Has Concluded.
▫️The Expert Group Was Established At The End of February 2021 To Look Into The Cause of The First 100 Reported Deaths of Nursing Home Residents Who Had Received The Pfizer-BioNTech Vaccine.
https://doi.org/10.1136/bmj.n1372
@MedicalNoteBook
▫️The Pfizer-BioNTech Covid-19 Vaccine Is “Likely” To Have Been Responsible For At Least 10 Deaths of Frail Elderly People In Nursing Homes In Norway, An Expert Review Commissioned by The Norwegian Medicines Agency Has Concluded.
▫️The Expert Group Was Established At The End of February 2021 To Look Into The Cause of The First 100 Reported Deaths of Nursing Home Residents Who Had Received The Pfizer-BioNTech Vaccine.
https://doi.org/10.1136/bmj.n1372
@MedicalNoteBook
The BMJ
Covid-19: Pfizer-BioNTech vaccine is “likely” responsible for deaths of some elderly patients, Norwegian review finds
The Pfizer-BioNTech covid-19 vaccine is “likely” to have been responsible for at least 10 deaths of frail elderly people in nursing homes in Norway, an expert review commissioned by the Norwegian Medicines Agency has concluded.
The expert group was established…
The expert group was established…
WHO Approves Sinovac Covid-19 Vaccine, The Second Chinese-Made Dose Listed
▫️The World Health Organization (WHO) Said on Tuesday It Has Approved A Covid-19 Vaccine Made by Drugmaker Sinovac Biotech for Emergency Use Listing, Paving The Way for A Second Chinese Shot To Be Used In Poor Countries.
▫️The Independent Panel of Experts Said In A Statement It Recommended Sinovac’s Vaccine for Adults Over 18, With A Second dose 2-4 Weeks Later.
▫️There Was No Upper Age Limit As Data Suggested It Is Likely To Have A Protective Effect In Older People.
▫️Branded CoronaVac In Some Regions, It Is The Second Chinese Developed Vaccine To Win Such WHO Listing To Combat Covid-19, After The May 7 Approval of A Shot Developed by State-Backed Sinopharm.
▫️A Third Chinese Vaccine, Produced by CanSino Biologics, Has Submitted Clinical Trial Data, But No WHO Review Has Been Scheduled.
@MedicalNoteBook
▫️The World Health Organization (WHO) Said on Tuesday It Has Approved A Covid-19 Vaccine Made by Drugmaker Sinovac Biotech for Emergency Use Listing, Paving The Way for A Second Chinese Shot To Be Used In Poor Countries.
▫️The Independent Panel of Experts Said In A Statement It Recommended Sinovac’s Vaccine for Adults Over 18, With A Second dose 2-4 Weeks Later.
▫️There Was No Upper Age Limit As Data Suggested It Is Likely To Have A Protective Effect In Older People.
▫️Branded CoronaVac In Some Regions, It Is The Second Chinese Developed Vaccine To Win Such WHO Listing To Combat Covid-19, After The May 7 Approval of A Shot Developed by State-Backed Sinopharm.
▫️A Third Chinese Vaccine, Produced by CanSino Biologics, Has Submitted Clinical Trial Data, But No WHO Review Has Been Scheduled.
@MedicalNoteBook
Pfizer Covid-19 Vaccine Linked To Myocarditis In Young Men, Says Israel's Health Ministry
▫️Israel Health Officials Have Found A Probable Link Between Pfizer And BioNTech Covid-19 Vaccine And dozens of Cases of Heart Inflammation In Young Men Following The Second dose of The Vaccine, The Health Ministry Said Late Tuesday.
▫️According To A Study by Health Officials, There Were 275 Cases of Myocarditis Identified Between December 2020, When The Vaccination Drive Began, And May 2021, Including 148 Cases Within A Month After Vaccination.
- Of These, 27 Cases Occurred After The First dose And 121 following The Second dose.
▫️The Study found “There Is A Probable Link Between Receiving The Second dose of Pfizer Covid-19 Vaccine And The Appearance of Myocarditis Among Men Aged 16 To 30,” It Said In A Statement. According To The Findings, Such A Link Was Observed More Among Men Aged 16 To 19 Than In Other Age Groups.
@MedicalNoteBook
▫️Israel Health Officials Have Found A Probable Link Between Pfizer And BioNTech Covid-19 Vaccine And dozens of Cases of Heart Inflammation In Young Men Following The Second dose of The Vaccine, The Health Ministry Said Late Tuesday.
▫️According To A Study by Health Officials, There Were 275 Cases of Myocarditis Identified Between December 2020, When The Vaccination Drive Began, And May 2021, Including 148 Cases Within A Month After Vaccination.
- Of These, 27 Cases Occurred After The First dose And 121 following The Second dose.
▫️The Study found “There Is A Probable Link Between Receiving The Second dose of Pfizer Covid-19 Vaccine And The Appearance of Myocarditis Among Men Aged 16 To 30,” It Said In A Statement. According To The Findings, Such A Link Was Observed More Among Men Aged 16 To 19 Than In Other Age Groups.
@MedicalNoteBook
Metal Ions Help Covid-19 Virus To Disguise Itself: Positively Charged Atoms Steady The Machinery That The Virus Uses To Trick The System
▫️Scientists from The University of Texas Health Science Center At San Antonio Have Discovered A Mechanism by Which SARS-CoV-2 Exploits Changes In Metal Ion Concentrations To Disguise Itself In The Body. Varying Concentrations of Metal Ions - Positively Charged Atoms Such As Magnesium, Manganese And Calcium - Are Observed In Hospitalized Covid-19 Patients. See More
@MedicalNoteBook
▫️Scientists from The University of Texas Health Science Center At San Antonio Have Discovered A Mechanism by Which SARS-CoV-2 Exploits Changes In Metal Ion Concentrations To Disguise Itself In The Body. Varying Concentrations of Metal Ions - Positively Charged Atoms Such As Magnesium, Manganese And Calcium - Are Observed In Hospitalized Covid-19 Patients. See More
@MedicalNoteBook
Nature Communications
A metal ion orients SARS-CoV-2 mRNA to ensure accurate 2′-O methylation of its first nucleotide
Nature Communications - The SARS-CoV-2 nsp16/nsp10 enzyme complex methylates the 2′-OH of the first nucleotide of the viral mRNA, converting the Cap-0 to Cap-1, which helps the virus to...
Study Confirms Poor Immunogenicity In Hemodialysis Patients Receiving Single dose Pfizer Covid-19 Vaccine
▫️Researchers From Ontario, Canada, Recently Conducted A Prospective Observational Study To Determine The SARS-CoV-2 Antibody Response In Chronic Hemodialysis Patients Following One vs. Two doses of The Pfizer Covid-19 Vaccine. The Results Were Compared To Health Care Worker Controls And Convalescent Serum.
▫️The Results Showed That 6% of Those Receiving One dose of The Vaccine Had An Anti-RBD Response Above The Median Level of Convalescent Serum vs. 41% of Those Who Received Two doses of The Vaccine.
▫️This Study Is Published on The PrePrint Server, MedRxiv.
@MedicalNoteBook
▫️Researchers From Ontario, Canada, Recently Conducted A Prospective Observational Study To Determine The SARS-CoV-2 Antibody Response In Chronic Hemodialysis Patients Following One vs. Two doses of The Pfizer Covid-19 Vaccine. The Results Were Compared To Health Care Worker Controls And Convalescent Serum.
▫️The Results Showed That 6% of Those Receiving One dose of The Vaccine Had An Anti-RBD Response Above The Median Level of Convalescent Serum vs. 41% of Those Who Received Two doses of The Vaccine.
▫️This Study Is Published on The PrePrint Server, MedRxiv.
@MedicalNoteBook
medRxiv
The Humoral Response to the BNT162b2 Vaccine in Hemodialysis Patients
Importance Hemodialysis patients have an exceptionally high mortality from COVID-19 and this patient population often has a poor response to vaccinations. Randomized controlled trials for COVID-19 vaccines included few patients with kidney disease, therefore…
FDA Approves Amgen Drug For Lung Cancer With Specific Mutation
▫️The U.S. Food And Drug Administration (FDA) on Friday Approved An Amgen Inc Drug for Non-Small Cell Lung Cancer With A Specific Mutation In A Gene Known As KRAS In Patients Whose Disease Has Worsened After Treatment With Chemotherapy Or Other Medicines.
▫️The Drug, Sotorasib, Which Will Be Sold Under The Brand Name Lumakras, Shrank Tumors With The KRAS Mutation In Around 36% of Patients In Clinical Trials.
▫️The Medication Is Designed To Target A Gene Mutation Known As KRAS G12C That Occurs In About 13% of Non-Small Cell Lung Cancers (NSCLC), The Most Common Type of Lung Cancer.
▫️Amgen Said The Drug Will Have U.S. List Price of $17,900 Per Month.
▫️The Approval, Which Comes More Than Two Months Before The FDA’s Target Decision Date, Is For A Daily 960 Milligram Pill.
@MedicalNewsToday
▫️The U.S. Food And Drug Administration (FDA) on Friday Approved An Amgen Inc Drug for Non-Small Cell Lung Cancer With A Specific Mutation In A Gene Known As KRAS In Patients Whose Disease Has Worsened After Treatment With Chemotherapy Or Other Medicines.
▫️The Drug, Sotorasib, Which Will Be Sold Under The Brand Name Lumakras, Shrank Tumors With The KRAS Mutation In Around 36% of Patients In Clinical Trials.
▫️The Medication Is Designed To Target A Gene Mutation Known As KRAS G12C That Occurs In About 13% of Non-Small Cell Lung Cancers (NSCLC), The Most Common Type of Lung Cancer.
▫️Amgen Said The Drug Will Have U.S. List Price of $17,900 Per Month.
▫️The Approval, Which Comes More Than Two Months Before The FDA’s Target Decision Date, Is For A Daily 960 Milligram Pill.
@MedicalNewsToday
Link Between Paracetamol Use During Pregnancy, Autism And ADHD Symptoms Supported by New Study
▫️In A Recently Published Epidemiological Study In The European Journal of Epidemiology, Researchers Confirmed That The Use of Paracetamol During Pregnancy Led To An Increased Risk of Children Displaying Symptoms of Attention-deficit Hyperactivity Disorder (ADHD) And Autism Spectrum Conditions (ASC).
▫️Researchers At The Barcelona Institute for Global Health, Have Carried Out An Epidemiological Study That They Claim Addresses Some Weaknesses of Previous, Similar Studies, And Supports A Proposed Link Between Maternal Use Of Paracetamol (Acetaminophen) During Pregnancy, And Symptoms of Attention-Deficit Hyperactivity Disorder (ADHD) And Autism Spectrum Conditions (ASC) In Their Children.
▫️The Newly Reported Study, Which Included More Than 70,000 Children In Six European Cohorts, Found That Children Exposed To Paracetamol Before Birth Were 19% More Likely To Develop ASC Symptoms And 21% More Likely To Develop ADHD Symptoms Than Those Who Were Not Exposed.
@MedicalNoteBook
▫️In A Recently Published Epidemiological Study In The European Journal of Epidemiology, Researchers Confirmed That The Use of Paracetamol During Pregnancy Led To An Increased Risk of Children Displaying Symptoms of Attention-deficit Hyperactivity Disorder (ADHD) And Autism Spectrum Conditions (ASC).
▫️Researchers At The Barcelona Institute for Global Health, Have Carried Out An Epidemiological Study That They Claim Addresses Some Weaknesses of Previous, Similar Studies, And Supports A Proposed Link Between Maternal Use Of Paracetamol (Acetaminophen) During Pregnancy, And Symptoms of Attention-Deficit Hyperactivity Disorder (ADHD) And Autism Spectrum Conditions (ASC) In Their Children.
▫️The Newly Reported Study, Which Included More Than 70,000 Children In Six European Cohorts, Found That Children Exposed To Paracetamol Before Birth Were 19% More Likely To Develop ASC Symptoms And 21% More Likely To Develop ADHD Symptoms Than Those Who Were Not Exposed.
@MedicalNoteBook
SpringerLink
Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms…
European Journal of Epidemiology - The potential etiological role of early acetaminophen exposure on Autism Spectrum Conditions (ASC) and Attention-Deficit/Hyperactivity Disorder (ADHD) is...
AstraZeneca's Lynparza Reduces Relapse, Death In Breast Cancer Patients
▫️AstraZeneca Drug Lynparza (Olaparib) Reduced The Risk of Relapse And Death In Breast Cancer Patients With Certain Mutations In A Late-Stage Trial, The British Drugmaker Said on Thursday.
▫️The Results, Published In The New England Journal of Medicine, Showed That The Drug Reduced The Combined Risk of Recurrence of Cancer Or Death from Any Cause by 42% Compared To A Placebo.
▫️Lynparza, Developed With Merck & Co Inc, Generated More Than $1 Billion In Sales Last Year For AstraZeneca And Has Become One of The Top Growth Drivers for The Drugmaker.
▫️The Treatment Belongs To A Class of Drugs Called PRAP Inhibitors That Stop Cancer Cells from Repairing Themselves After Damage from Chemotherapy.
@MedicalNoteBook
▫️AstraZeneca Drug Lynparza (Olaparib) Reduced The Risk of Relapse And Death In Breast Cancer Patients With Certain Mutations In A Late-Stage Trial, The British Drugmaker Said on Thursday.
▫️The Results, Published In The New England Journal of Medicine, Showed That The Drug Reduced The Combined Risk of Recurrence of Cancer Or Death from Any Cause by 42% Compared To A Placebo.
▫️Lynparza, Developed With Merck & Co Inc, Generated More Than $1 Billion In Sales Last Year For AstraZeneca And Has Become One of The Top Growth Drivers for The Drugmaker.
▫️The Treatment Belongs To A Class of Drugs Called PRAP Inhibitors That Stop Cancer Cells from Repairing Themselves After Damage from Chemotherapy.
@MedicalNoteBook
The New England Journal of Medicine
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects
in homologous recombination repair by synthetic lethality. New therapies are needed
to reduce recurrence in pati...
in homologous recombination repair by synthetic lethality. New therapies are needed
to reduce recurrence in pati...
People Who Received Pfizer Covid-19 Vaccine Have Lower Antibody Levels Targeting The Delta Variant
▫️Levels of Antibodies In The Blood of Vaccinated People That Are Able To Recognize And Fight The New SARS-CoV-2 Delta Variant First Discovered In India (B.1.617.2) Are On Average Lower Than Those Against Previously Circulating Variants In The UK, According To New Laboratory Data from The Francis Crick Institute And The National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, Published As A Research Letter In The Lancet.
▫️They Found That In People Who Had Been Fully Vaccinated With Two doses of The Pfizer-BioNTech Vaccine, Levels of Neutralizing Antibodies Were More Than Five Times Lower Against The B.1.617.2 Variant When Compared To The Original Strain, Upon Which Current Vaccines Are Based.
▫️After A Single dose of Pfizer-BioNTech, 79% of People Had A Quantifiable Neutralising Antibody Response Against The Original Strain, But This Fell To 50% For B.1.1.7, 32% For B.1.617.2 And 25% for B.1.351.
▫️The Results Also Show That Levels of These Antibodies Are Lower With Increasing Age And That Levels Decline Over Time, Providing Additional Evidence In Support of Plans To Deliver A Vaccination Boost To Vulnerable People In The Autumn.
@MedicalNoteBook
▫️Levels of Antibodies In The Blood of Vaccinated People That Are Able To Recognize And Fight The New SARS-CoV-2 Delta Variant First Discovered In India (B.1.617.2) Are On Average Lower Than Those Against Previously Circulating Variants In The UK, According To New Laboratory Data from The Francis Crick Institute And The National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, Published As A Research Letter In The Lancet.
▫️They Found That In People Who Had Been Fully Vaccinated With Two doses of The Pfizer-BioNTech Vaccine, Levels of Neutralizing Antibodies Were More Than Five Times Lower Against The B.1.617.2 Variant When Compared To The Original Strain, Upon Which Current Vaccines Are Based.
▫️After A Single dose of Pfizer-BioNTech, 79% of People Had A Quantifiable Neutralising Antibody Response Against The Original Strain, But This Fell To 50% For B.1.1.7, 32% For B.1.617.2 And 25% for B.1.351.
▫️The Results Also Show That Levels of These Antibodies Are Lower With Increasing Age And That Levels Decline Over Time, Providing Additional Evidence In Support of Plans To Deliver A Vaccination Boost To Vulnerable People In The Autumn.
@MedicalNoteBook
Sciencedirect
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
Prior Covid-19 Infection Reduces Infection Risk For Up To 10 Months
▫️The Risk of Being Infected With SARS-CoV-2, The Virus That Causes Covid-19, Is Substantially Reduced For Up To 10 Months Following A First Infection, According To New Findings Led by UCL Researchers.
▫️For The Study, Published In Lancet Healthy Longevity, Researchers Looked At Rates of Covid-19 Infections Between October And February Among More Than 2,000 Care Home Residents And Staff, Comparing Those Who Had Evidence of A Previous Infection Up To 10 Months Earlier, As Determined by Antibody Testing, With Those Who Had Not Been Previously Infected.
@MedicalNoteBook
▫️The Risk of Being Infected With SARS-CoV-2, The Virus That Causes Covid-19, Is Substantially Reduced For Up To 10 Months Following A First Infection, According To New Findings Led by UCL Researchers.
▫️For The Study, Published In Lancet Healthy Longevity, Researchers Looked At Rates of Covid-19 Infections Between October And February Among More Than 2,000 Care Home Residents And Staff, Comparing Those Who Had Evidence of A Previous Infection Up To 10 Months Earlier, As Determined by Antibody Testing, With Those Who Had Not Been Previously Infected.
@MedicalNoteBook
FDA Approves Ibrexafungerp for Vaginal Yeast Infection
▫️The US Food And Drug Administration (FDA) Has Approved Ibrexafungerp Tablets (Brexafemme) As A 1-day Oral Therapy For Vaginal Yeast Infections, Something 3 Out of Every 4 Women Encounter At Least Once In Their Life.
▫️Ibrexafungerp Is The First Drug Approved In A New Antifungal Class for The Condition, formally Known As Vulvovaginal Candidiasis (VVC), In More Than 20 Years, The Drug's Manufacturer Scynexis Said In A Press Release. It Becomes The First And Only Non-Azole Treatment for Vaginal Yeast Infections.
▫️The Biotechnology Company Said Approval Came After Positive Results from Two Phase 3 Studies In Which Oral Ibrexafungerp Demonstrated Efficacy And Tolerability. The Most Common Reactions Observed In Clinical Trials Were Diarrhea, Nausea, Abdominal Pain, Dizziness, And Vomiting.
▫️The New Drug May Not Fill That Need for Pregnant Women, However, As The Company Notes Ibrexafungerp Should Not Be Used During Pregnancy, And Administration During Pregnancy "May Cause Fetal Harm Based On Animal Studies."
▫️Because of Possible Teratogenic Effects, The Company Advises Clinicians To Verify Pregnancy Status In Females of Reproductive Potential Before Prescribing Ibrexafungerp And Advises Effective Contraception During Treatment.
@MedicalNoteBook
▫️The US Food And Drug Administration (FDA) Has Approved Ibrexafungerp Tablets (Brexafemme) As A 1-day Oral Therapy For Vaginal Yeast Infections, Something 3 Out of Every 4 Women Encounter At Least Once In Their Life.
▫️Ibrexafungerp Is The First Drug Approved In A New Antifungal Class for The Condition, formally Known As Vulvovaginal Candidiasis (VVC), In More Than 20 Years, The Drug's Manufacturer Scynexis Said In A Press Release. It Becomes The First And Only Non-Azole Treatment for Vaginal Yeast Infections.
▫️The Biotechnology Company Said Approval Came After Positive Results from Two Phase 3 Studies In Which Oral Ibrexafungerp Demonstrated Efficacy And Tolerability. The Most Common Reactions Observed In Clinical Trials Were Diarrhea, Nausea, Abdominal Pain, Dizziness, And Vomiting.
▫️The New Drug May Not Fill That Need for Pregnant Women, However, As The Company Notes Ibrexafungerp Should Not Be Used During Pregnancy, And Administration During Pregnancy "May Cause Fetal Harm Based On Animal Studies."
▫️Because of Possible Teratogenic Effects, The Company Advises Clinicians To Verify Pregnancy Status In Females of Reproductive Potential Before Prescribing Ibrexafungerp And Advises Effective Contraception During Treatment.
@MedicalNoteBook
Preliminary Analysis of Association Between mRNA Vaccines And Sudden Hearing Loss
▫️In A New Study, Johns Hopkins Medicine Researchers Have Tried To Address Recent Reports That Sudden Sensorineural Hearing Loss - A Condition That Occurs As A Result of Damage To The Inner Ear - Has Been Suspected of Being A Potential Side Effect of Vaccination Against SARS-CoV-2, The Virus That Causes Covid-19.
▫️Out of More Than 86.5 Million Vaccine doses Administered During The Study Period, The Researchers Identified 40 Cases of Sensorineural Hearing Loss (SSNHL) That Appeared "Most Likely" To Be Linked To Vaccination Because They Had A Temporal Association, Occurring Within Three Weeks of Receipt of SARS-CoV-2 mRNA Vaccines, and were reported and documented by a healthcare clinician.
▫️Because VAERS Data Is Unverified, The Authors Performed A Sensitivity Analysis And Came Up With A Minimum Incidence Rate of 0.3 Per 100,000 Per Year, And A Maximum Incidence of 4.1 Per 100,000 Per Year.
- That Is Still Lower Than The Known Population Incidence of SSNHL, Which Ranges from Roughly 11 To 77 Per 100,000 Depending on Age Group, They Note In JAMA Otolaryngology-Head & Neck Surgery.
@MedicalNoteBook
▫️In A New Study, Johns Hopkins Medicine Researchers Have Tried To Address Recent Reports That Sudden Sensorineural Hearing Loss - A Condition That Occurs As A Result of Damage To The Inner Ear - Has Been Suspected of Being A Potential Side Effect of Vaccination Against SARS-CoV-2, The Virus That Causes Covid-19.
▫️Out of More Than 86.5 Million Vaccine doses Administered During The Study Period, The Researchers Identified 40 Cases of Sensorineural Hearing Loss (SSNHL) That Appeared "Most Likely" To Be Linked To Vaccination Because They Had A Temporal Association, Occurring Within Three Weeks of Receipt of SARS-CoV-2 mRNA Vaccines, and were reported and documented by a healthcare clinician.
▫️Because VAERS Data Is Unverified, The Authors Performed A Sensitivity Analysis And Came Up With A Minimum Incidence Rate of 0.3 Per 100,000 Per Year, And A Maximum Incidence of 4.1 Per 100,000 Per Year.
- That Is Still Lower Than The Known Population Incidence of SSNHL, Which Ranges from Roughly 11 To 77 Per 100,000 Depending on Age Group, They Note In JAMA Otolaryngology-Head & Neck Surgery.
@MedicalNoteBook
Sinovac’s Covid-19 Vaccine Gains China Nod for Emergency Use In Kids, Adolescents
▫️China Has Approved Emergency Use of Sinovac Biotech’s Covid-19 Vaccine In People Aged Between Three And 17, Its Chairman Yin Weidong Told State TV Late on Friday.
▫️China's Mass Vaccination Drive, Which Administered 723.5 Million doses of Vaccines As of June 3, Is Currently Only Open To Those Aged 18 And Above.
▫️Preliminary Results From Phase I And II Clinical Trials Showed The Vaccine Could Trigger Immune Response In Three To 17 Year-Old Participants, And Most Adverse Reactions Were Mild.
▫️State-Backed Drugmaker Sinopharm, Which Has Two Shots Using Similar Technology To Sinovac's Product, Is Also Submitting Data For Clearance In Younger Groups. A Vaccine from CanSino Biologics', Adopting A Different Technique, Has Entered A Phase II Trial Involving Those Aged Between Six And 17.
@MedicalNoteBook
▫️China Has Approved Emergency Use of Sinovac Biotech’s Covid-19 Vaccine In People Aged Between Three And 17, Its Chairman Yin Weidong Told State TV Late on Friday.
▫️China's Mass Vaccination Drive, Which Administered 723.5 Million doses of Vaccines As of June 3, Is Currently Only Open To Those Aged 18 And Above.
▫️Preliminary Results From Phase I And II Clinical Trials Showed The Vaccine Could Trigger Immune Response In Three To 17 Year-Old Participants, And Most Adverse Reactions Were Mild.
▫️State-Backed Drugmaker Sinopharm, Which Has Two Shots Using Similar Technology To Sinovac's Product, Is Also Submitting Data For Clearance In Younger Groups. A Vaccine from CanSino Biologics', Adopting A Different Technique, Has Entered A Phase II Trial Involving Those Aged Between Six And 17.
@MedicalNoteBook
New Antibody Drug Keeps Mild Covid-19 From Worsening
▫️An Antibody Drug from Vir Biotechnology And GlaxoSmithKline That Protects Against Progression of Covid-19 In High-Risk Patients With Mild To Moderate Disease Has Received Emergency Use Authorization by The U.S. Food And Drug Administration (FDA).
▫️In A Large Randomized Trial, Patient Risk of Progression To More Severe illness Was Reduced by 85% With The Drug, Sotrovimab, Compared To A Placebo, According To An Interim Report from The Trial Posted on The medRxiv Website In Advance of Peer Review.
▫️Sotrovimab, The Antibody Treatment, Is Not Authorized For Patients Who Are Hospitalized Due To Covid-19 Or Require Oxygen Therapy, According To The Agency.
@MedicalNoteBook
▫️An Antibody Drug from Vir Biotechnology And GlaxoSmithKline That Protects Against Progression of Covid-19 In High-Risk Patients With Mild To Moderate Disease Has Received Emergency Use Authorization by The U.S. Food And Drug Administration (FDA).
▫️In A Large Randomized Trial, Patient Risk of Progression To More Severe illness Was Reduced by 85% With The Drug, Sotrovimab, Compared To A Placebo, According To An Interim Report from The Trial Posted on The medRxiv Website In Advance of Peer Review.
▫️Sotrovimab, The Antibody Treatment, Is Not Authorized For Patients Who Are Hospitalized Due To Covid-19 Or Require Oxygen Therapy, According To The Agency.
@MedicalNoteBook
medRxiv
Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab
Background Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization and death in older patients and those with underlying comorbidities. Sotrovimab is a pan-sarbecovirus monoclonal antibody designed to treat such high-risk patients…
Study: Nasal Therapy Is More Effective Than Commonly Used IgG Antibodies At Neutralizing Covid-19 Virus
▫️A Nasal Therapy, Built Upon on The Application of A New Engineered IgM Antibody Therapy for Covid-19, Was More Effective Than Commonly Used IgG Antibodies At Neutralizing The Covid-19 Virus In Animal Models, According To Research Recently Published by The University of Texas Health Science Center At Houston, The University of Texas Medical Branch At Galveston, The University of Houston, And IGM Biosciences, Inc.
▫️The Study Was Published In Nature.
@MedicalNewsToday
▫️A Nasal Therapy, Built Upon on The Application of A New Engineered IgM Antibody Therapy for Covid-19, Was More Effective Than Commonly Used IgG Antibodies At Neutralizing The Covid-19 Virus In Animal Models, According To Research Recently Published by The University of Texas Health Science Center At Houston, The University of Texas Medical Branch At Galveston, The University of Houston, And IGM Biosciences, Inc.
▫️The Study Was Published In Nature.
@MedicalNewsToday
Nature
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
This is an unedited manuscript that has been accepted for publication. Nature Research are providing this early version of the manuscript as a service to our authors and readers. The manuscript will undergo copyediting, typesetting and a proof review before…
FDA Approved Novo Nordisk's Once-Weekly Semaglutide For Weight Loss
▫️The U.S. Food And Drug Administration (FDA) Has Approved Once-weekly Semaglutide Injection for Chronic Weight Management In Adults With Obesity Or With Overweight And At Least One Weight-Related Condition, According To An Agency Press Release.
▫️Weekly Semaglutide 2.4 mg (Wegovy, Novo Nordisk), A GLP-1 Receptor Agonist, Is The First-Approved Drug For Chronic Weight Management In Adults With General Obesity Or Overweight Since 2014.
▫️Semaglutide Is Indicated For Chronic Weight Management In Adults With A BMI of 27 kg/m² Or Greater Who Have At Least One Weight-Related Comorbidity, Such As Type 2 Diabetes Or Hypertension, Or In Adults With A BMI Of At Least 30 kg/m².
@MedicalNoteBook
▫️The U.S. Food And Drug Administration (FDA) Has Approved Once-weekly Semaglutide Injection for Chronic Weight Management In Adults With Obesity Or With Overweight And At Least One Weight-Related Condition, According To An Agency Press Release.
▫️Weekly Semaglutide 2.4 mg (Wegovy, Novo Nordisk), A GLP-1 Receptor Agonist, Is The First-Approved Drug For Chronic Weight Management In Adults With General Obesity Or Overweight Since 2014.
▫️Semaglutide Is Indicated For Chronic Weight Management In Adults With A BMI of 27 kg/m² Or Greater Who Have At Least One Weight-Related Comorbidity, Such As Type 2 Diabetes Or Hypertension, Or In Adults With A BMI Of At Least 30 kg/m².
@MedicalNoteBook
New Non-Invasive Test Can Detect Bladder Cancer
▫️A Novel Urine Screening Test That Uses A Protein, Keratin 17 (K17), As A Cancer Biomarker Reveals The Test Detects The Presence of New Or Recurrent Cases of Bladder Cancer.
▫️A Study That Details The Finding of The Test Will Be Published In The American Journal of Clinical Pathology.
▫️Accurate Detection Of Bladder Cancer, Or Urothelial Carcinoma (UC), Is Often Difficult, Expensive And Involves Invasive Testing. Going Forward, This New Method, Based on The Detection of K17 In Urine Specimens, Could Help Guide Treatment By Improving Diagnostic Accuracy.
@MedicalNoteBook
▫️A Novel Urine Screening Test That Uses A Protein, Keratin 17 (K17), As A Cancer Biomarker Reveals The Test Detects The Presence of New Or Recurrent Cases of Bladder Cancer.
▫️A Study That Details The Finding of The Test Will Be Published In The American Journal of Clinical Pathology.
▫️Accurate Detection Of Bladder Cancer, Or Urothelial Carcinoma (UC), Is Often Difficult, Expensive And Involves Invasive Testing. Going Forward, This New Method, Based on The Detection of K17 In Urine Specimens, Could Help Guide Treatment By Improving Diagnostic Accuracy.
@MedicalNoteBook
OUP Academic
Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis
AbstractObjectives. The microscopic features of urine cytology specimens are subjective and may not reliably distinguish between benign urothelial cells and low
A Novel Tuberculosis Regimen Shortens Treatment Course For Patients
▫️A Research Team Led by A Medical University of South Carolina (MUSC) Investigator Reports In The May 6 Issue of The New England Journal of Medicine That A Four-Month Treatment Regimen Using Rifapentine Is Effective for Treating Tuberculosis (TB).
▫️The Current Treatment for Those With An Active TB Infection Is A Multidrug Regimen Over The Course of Six To Nine Months.
@MedicalNoteBook
▫️A Research Team Led by A Medical University of South Carolina (MUSC) Investigator Reports In The May 6 Issue of The New England Journal of Medicine That A Four-Month Treatment Regimen Using Rifapentine Is Effective for Treating Tuberculosis (TB).
▫️The Current Treatment for Those With An Active TB Infection Is A Multidrug Regimen Over The Course of Six To Nine Months.
@MedicalNoteBook
New England Journal of Medicine
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis | NEJM
Original Article from The New England Journal of Medicine — Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Mental Health Effects Common Among Mild And Severe Cases of Covid-19
▫️In A Study Published In The Journal of Neurology, Neurosurgery, And Psychiatry, Have Reported That Neurological And Psychiatric Symptoms Are Common Among People With Covid-19 And Maybe Just As Likely In People With Mild Cases.
▫️The Researchers Conducted A Meta-Analysis of 215 Covid-19-Related Studies Using Data Up To July 2020 from 30 Countries And Encompassing 105,638 People With Acute Symptoms of Covid-19.
▫️Across The Whole Dataset, The Most Common Neurological And Psychiatric Symptoms Were A Loss of Smell; Reported by 43% of Patients With Covid-19, Weakness (40%), Fatigue (38%), Loss of Taste; (37%), Myalgia (Muscle Pain; 25%), Depression (23%), Headache (21%) And Anxiety (16%).
@MedicalNoteBook
▫️In A Study Published In The Journal of Neurology, Neurosurgery, And Psychiatry, Have Reported That Neurological And Psychiatric Symptoms Are Common Among People With Covid-19 And Maybe Just As Likely In People With Mild Cases.
▫️The Researchers Conducted A Meta-Analysis of 215 Covid-19-Related Studies Using Data Up To July 2020 from 30 Countries And Encompassing 105,638 People With Acute Symptoms of Covid-19.
▫️Across The Whole Dataset, The Most Common Neurological And Psychiatric Symptoms Were A Loss of Smell; Reported by 43% of Patients With Covid-19, Weakness (40%), Fatigue (38%), Loss of Taste; (37%), Myalgia (Muscle Pain; 25%), Depression (23%), Headache (21%) And Anxiety (16%).
@MedicalNoteBook
Journal of Neurology, Neurosurgery & Psychiatry
Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations…
There is accumulating evidence of the neurological and neuropsychiatric features of infection with SARS-CoV-2. In this systematic review and meta-analysis, we aimed to describe the characteristics of the early literature and estimate point prevalences for…
Heterologous Oxford And Pfizer Covid-19 Vaccines Induce Strong Immune Response And T Cell Reactivity Against Multiple SARS-CoV-2 Variants
▫️Researchers From Germany Recently Analyzed A Cohort of 26 Individuals In The Age Range of 25 to 46 (Median 30.5) Years Who Had Received A ChAdOx1 nCoV-19 (Vaxzevria, Oxford-AstraZeneca) Prime Vaccine Followed by A BNT162b2 (Comirnaty, BioNTech-Pfizer) Boost Vaccine After A 56-day Interval Due To Changing Vaccine Recommendations In Germany.
▫️There Were 16 Females And 10 Males In The Cohort, And They Were Assessed For Immune Responses, Reactogenicity, And T Cell Reactivity. This Study is Published on The medRxiv PrePrint Server.
▫️The Results Show That, Neutralizing Activity Against The UK Variant B.1.1.7 In Individuals Receiving Heterologous Vaccination Was 3.9-Fold Greater Than That In Individuals Receiving Homologous BNT162b2 Vaccination.
▫️Neutralizing Activity Was 2-Fold Reduced for The South African Variant B.1.351 And Was Similar for The B.1.617 Variant.
▫️To Summarize, The Heterologous ChAdOx1 nCoV-19 - BNT162b2 Prime-Boost Vaccination Regimen Did Not Cause Serious Adverse Events And Elicited A Potent Humoral Immune Response And T Cell Reactivity.
@MedicalNoteBook
▫️Researchers From Germany Recently Analyzed A Cohort of 26 Individuals In The Age Range of 25 to 46 (Median 30.5) Years Who Had Received A ChAdOx1 nCoV-19 (Vaxzevria, Oxford-AstraZeneca) Prime Vaccine Followed by A BNT162b2 (Comirnaty, BioNTech-Pfizer) Boost Vaccine After A 56-day Interval Due To Changing Vaccine Recommendations In Germany.
▫️There Were 16 Females And 10 Males In The Cohort, And They Were Assessed For Immune Responses, Reactogenicity, And T Cell Reactivity. This Study is Published on The medRxiv PrePrint Server.
▫️The Results Show That, Neutralizing Activity Against The UK Variant B.1.1.7 In Individuals Receiving Heterologous Vaccination Was 3.9-Fold Greater Than That In Individuals Receiving Homologous BNT162b2 Vaccination.
▫️Neutralizing Activity Was 2-Fold Reduced for The South African Variant B.1.351 And Was Similar for The B.1.617 Variant.
▫️To Summarize, The Heterologous ChAdOx1 nCoV-19 - BNT162b2 Prime-Boost Vaccination Regimen Did Not Cause Serious Adverse Events And Elicited A Potent Humoral Immune Response And T Cell Reactivity.
@MedicalNoteBook
medRxiv
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity
Heterologous COVID-19 vaccination regimens combining vector- and mRNA-based vaccines are already administered, but data on solicited adverse reactions, immunological responses and elicited protection are limited. We aimed to evaluate the reactogenicity, humoral…
US FDA Approves Biogen's Alzheimer's Disease Drug Aducanumab
▫️U.S. Food And Drug Administration (FDA) On Monday Approved Biogen Inc's Aducanumab As The First Treatment To Address An Underlying Cause of Alzheimer's Disease Despite Controversy Over Mixed Clinical Trial Results for The Drug.
▫️Aducanumab Aims To Remove Sticky Deposits of A Protein Called Amyloid Beta From The Brains of Patients In Earlier Stages of Alzheimer's In Order To Stave off Its Ravages, Which Include Memory Loss And The Ability To Care for One's Self.
▫️The FDA Said Clinical Trials For The Treatment, To Be Sold Under The Brand Name Aduhelm, Showed A Reduction In The Plaques That Is Expected To Lead To A Reduction In The Clinical Decline of Patients.
▫️Aducanumab Was Studied In Patients With Early Disease Who Test Positive for A Component of Amyloid Brain Plaques. Some Trial Patients Experienced Potentially Dangerous Brain Swelling.
@MedicalNoteBook
▫️U.S. Food And Drug Administration (FDA) On Monday Approved Biogen Inc's Aducanumab As The First Treatment To Address An Underlying Cause of Alzheimer's Disease Despite Controversy Over Mixed Clinical Trial Results for The Drug.
▫️Aducanumab Aims To Remove Sticky Deposits of A Protein Called Amyloid Beta From The Brains of Patients In Earlier Stages of Alzheimer's In Order To Stave off Its Ravages, Which Include Memory Loss And The Ability To Care for One's Self.
▫️The FDA Said Clinical Trials For The Treatment, To Be Sold Under The Brand Name Aduhelm, Showed A Reduction In The Plaques That Is Expected To Lead To A Reduction In The Clinical Decline of Patients.
▫️Aducanumab Was Studied In Patients With Early Disease Who Test Positive for A Component of Amyloid Brain Plaques. Some Trial Patients Experienced Potentially Dangerous Brain Swelling.
@MedicalNoteBook